New CAR t therapy aims to tackle tough multiple myeloma
NCT ID NCT07421856
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial is testing a new treatment called SENL103 for people with multiple myeloma that has returned or not responded to standard treatments. The treatment uses a patient's own immune cells, modified to target and attack cancer cells. The study will enroll 24 participants to check safety and how well the therapy works.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- SENL103 autologous BCMA-targeting CAR T cells
- What this could lead to
- If successful, this could offer a new treatment option for patients with multiple myeloma that has come back or not responded to other therapies.
- What could go wrong
- This is an early-phase trial with only 24 participants, so results may not apply to everyone. There are risks of serious side effects like cytokine release syndrome and neurotoxicity.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA IN RELAPSE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Triple-Drug cocktail tame resistant myeloma?
- Can a single gene therapy turn the body into a Cancer-Fighting factory?
- Engineered immune cells take on incurable blood cancer
- New CAR T-Cell therapy targets Hard-to-Treat myeloma
- New 'Off-the-Shelf' CAR-T therapy takes on Hard-to-Treat myeloma
- Why do blood cancer patients skip home care? new study aims to find out.